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A substantial proportion of patients with heart failure remain either not eligible 
for cardiac resynchronization therapy (CRT) or do not respond to this therapy. CRT 
is indicated in patients with prolonged QRS duration (>120 ms).1 However, up to 
60% of patients with heart failure have a normal QRS duration and are not appropri-
ate candidates for CRT. In addition, a significant number of patients (25-30%) who 
meet the current indications to CRT therapy are non-responders.2 New device-based 
therapies including cardiac contractility modulation (CCM) have been developed 
over the last decade.
Cardiac contractility modulation signals are non-excitatory signals which, when 
applied during the absolute refractory period, enhance the strength of left ventricular 
(LV) contraction. CCM signals are electrical impulses delivered during the absolute 
refractory period.3,4 CCM signals used in clinical practice are delivered 30 ms after 
detection of the QRS complex onset and consist of two biphasic +7 V pulses span-
ning a total duration of 20 ms. These signals do not elicit a new action potential or 
contraction.3,4
Preliminary data have shown that CCM improves LV cellular and biochemical 
remodelling. There is an increase in phosphorylation of phospholamban, a key protein 
that modulates the activity of sarco-endoplasmic reticulum calcium ATPase type 2a 
(SERCA2a), which in turn modulates calcium handling by the sarcoplasmic reticulum.5
Within several minutes of acute CCM signal application, a mild increase in ventricu-
lar contractile strength can be detected as indexed by increases in LV pressure and the 
rate of rise of LV pressure (LV dP/dtmax). The acute change dP/dtmax is independent 
of QRS duration.6 Acute CCM was associated with an increase in dP/dtmax from 630 
to 800 mmHg/s (20% increase). Despite an acute increase in contractility, there was 
no detectible increase in myocardial oxygen consumption.7 In a previous study, LV 
ejection fraction increased by 4.8±3.6% and LV end-systolic volumes decreased by 
11.5±10.5% at 3 months after CCM treatment.8 In the multicenter studies FIX-HF-4 
and FIX-HF-5, CCM increased peak oxygen consumption and improved quality of life 
in patients with heart failure.9,10 These findings indicate that LV reverse remodelling 
can be achieved by CCM in the background of optimum medical therapy.
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